Nyxoah SA
NYXH
1.37 EUR
1 Tag: -3.09% (-0.04 EUR)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer NYXH
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Aktuelle News
-
Dr. Andrew Patel and Oath Surgical Bring Sleep Apnea Implant to Oregon in a First for Pacific Northwest Outpatient Surgery
Vorschau anzeigen
SAN FRANCISCO, August 26, 2026--Oath Surgical today announced that Dr. Andrew Patel has performed the first of its kind implant procedure in Oregon and the first in the Pacific Northwest to take place in an ambulatory surgery center (ASC) setting. The milestone expands access to an innovative treatment option in a state where an estimated 1.1 million residents, or 31% of the population, have mild to severe obstructive sleep apnea (OSA), including approximately 165,000 people in Portland.
-
Information on the total number of voting rights and shares
Vorschau anzeigen
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), August 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 1,767,402 new shares on August 20, 2026 in connection with the contribution in kind of a receivable held by the holder of the convertible bon
-
Nyxoah SA (NYXH) (Q2 2026) Earnings Call Highlights: US Revenue Surges 22% Sequentially, $110M ...
Vorschau anzeigen
Nyxoah SA (NYXH) reports strong US commercial momentum with active accounts doubling to 180, while securing capital to accelerate its launch ramp.
-
Nyxoah Q2 Earnings Call Highlights
Vorschau anzeigen
Nyxoah (NASDAQ:NYXH) reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequen
-
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Vorschau anzeigen
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructi